UNTOUCHED Trial Shows Low Complication Rate With Boston Scientific’s Emblem S-ICD
Executive Summary
Procedural outcome data of the UNTOUCHED trial of the Emblem subcutaneous implantable cardioverter defibrillator show low perioperative complication rates and high conversion efficacy of induced ventricular fibrillation in a high-risk patient population.
You may also be interested in...
HRS 2020: Boston Scientific’s Emblem S-ICD Proves Safe And Effective In ‘Sickest Population’
Results of two studies presented at the Heart Rhythm Society Scientific Sessions support the subcutaneous implantable cardioverter defibrillator as an alternative to ICDs with transvenous leads.
Medtronic Expects EV ICD To Reduce ICD Complications, Costs
The pivotal trial of Medtronic’s EV ICD, an implantable cardioverter defibrillator without a transvenous lead, has begun with implants in Illinois and New Zealand. The study will measure device-related complications with the device over six months and test EV ICD's ability to stop ventricular fibrillation.
Medtronic’s Extravascular ICD Stops Ventricular Arrhythmias In Pilot Trial
In a 21-patient first in-human pilot trial, Medtronic’s Extravascular Implantable Cardioverter Defibrillator (EV ICD) system successfully terminated induced ventricular arrhythmias in 89.5% of patients and achieved pacing capture in 95% of patients.